152 Participants Needed

Deprexis for Depression

(Deprexis Trial)

RR
JF
Overseen ByJoseph F Maher
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: VA Office of Research and Development
Must be taking: Psychotropic medications
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but it mentions that participants should be stable on psychotropic medications. This suggests you may continue your current medications if they are stable.

How does the drug Deprexis differ from other treatments for depression?

Deprexis, also known as deprenyl or selegiline, is unique because it is a selective monoamine oxidase type B inhibitor (MAO-B inhibitor), which means it targets a specific enzyme involved in breaking down mood-related chemicals in the brain. Unlike other MAO inhibitors, it has fewer side effects and does not cause a hypertensive crisis (dangerously high blood pressure) when consuming certain foods.12345

What is the purpose of this trial?

Depressive symptoms are common among Veterans and associated with significant impairment. Timely intervention has the potential to improve mental health outcomes and restore functioning. Interventions delivered through the internet can be completed remotely at any time, and thus minimize burden on Veterans, however the research examining their utility in Veterans is limited. This proposed project will examine Deprexis, a self-guided internet-delivered intervention, which targets depressive symptoms and associated functional impairments. Interviews will be conducted to gain insight into Veterans' perceptions, needs, and preferences vis-a-vis Deprexis, with results informing a randomized controlled trial. Here an 8-week course of Deprexis will be compared to a treatment-as-usual (TAU) control condition to establish if Deprexis is acceptable and effective for Veterans with mild to moderate depressive symptoms. Veterans engaged in Deprexis are hypothesized to show improvements on measures of functioning and decreases in depressive symptoms compared to the TAU control group. The proposed work has great clinical utility, as it could provide a readily accessible, high-quality intervention for the many Veterans suffering from depressive symptoms, with the potential to improve functioning and long-term outcomes.

Research Team

RR

Rahel R Pearson, PhD

Principal Investigator

Central Texas Veterans Health Care System Waco VA Medical Center, Waco, TX

Eligibility Criteria

This trial is for Veterans experiencing mild to moderate depression. Participants should be interested in a self-guided, internet-based intervention and available for an 8-week course. Specific eligibility criteria are not provided, but typically participants would need access to the internet and have no conditions that significantly interfere with study participation.

Inclusion Criteria

I am a Veteran with mild or moderate depression.
Potential participants include male and female Veterans of all races/ethnicities who are able to comprehend and sign the informed consent form
Potential participants include male and female Veterans of all races/ethnicities who have reliable access to the internet and a computer, tablet and/or smartphone
See 1 more

Exclusion Criteria

Aim 1 and Aim 2: Veterans will be excluded from study participation if they report current suicidal risk
Aim 1 and Aim 2: Veterans will be excluded from study participation if they endorse any positive symptoms of a psychotic disorder
Aim 1 and Aim 2: Veterans will be excluded from study participation if they screen positive for Bipolar I Disorder

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive an 8-week course of Deprexis, a self-guided internet-delivered intervention, compared to a treatment-as-usual control condition

8 weeks
Remote access, self-guided

Follow-up

Participants are monitored for safety and effectiveness after treatment, with assessments at baseline, post-treatment, and 8-week follow-up

8 weeks
Remote assessments

Treatment Details

Interventions

  • Deprexis
Trial Overview The trial tests Deprexis, an online program designed to help manage depressive symptoms. Veterans will either use Deprexis or receive their usual treatment over eight weeks. The goal is to see if Deprexis can improve mental health outcomes and daily functioning more than standard treatments.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: DeprexisExperimental Treatment1 Intervention
Deprexis: an internet-delivered psychosocial treatment for depressive symptoms and related functional impairment.
Group II: Treatment-as-UsualActive Control1 Intervention
Access to standard non-study care

Deprexis is already approved in United States for the following indications:

🇺🇸
Approved in United States as Deprexis for:
  • Mild to moderate depressive symptoms

Find a Clinic Near You

Who Is Running the Clinical Trial?

VA Office of Research and Development

Lead Sponsor

Trials
1,691
Recruited
3,759,000+

Findings from Research

Selective monoamine oxidase inhibitors, such as deprenyl, have shown promise as adjuvant therapy in treating Parkinson's disease and depression due to their ability to inhibit dopamine oxidation.
Unlike traditional monoamine oxidase inhibitors, selective ones like deprenyl have a significant advantage of not causing a pressor response, making them safer for patients.
Monoamine oxidase inhibitors as anti-depressant drugs and as adjunct to L-dopa therapy of Parkinson's disease.Youdim, MB.[2019]
In a study of 11 parkinsonian patients over 4 weeks, (-)deprenyl showed mixed results, with some patients experiencing improvement in parkinsonian symptoms while others deteriorated, indicating limited overall efficacy.
The treatment was associated with side effects like euphoria and insomnia, and while it decreased plasma epinephrine and platelet MAO activity, it did not significantly increase catecholamine levels, suggesting its effects may be more related to mood elevation than direct improvement in parkinsonism.
Deprenyl in Parkinson disease.Eisler, T., Teräväinen, H., Nelson, R., et al.[2019]
In a double-blind placebo-controlled study, (-)-deprenyl (selegiline) showed significant antidepressant effects after six weeks at higher doses (around 30 mg/d), with a positive response rate of 50% compared to 13.6% for placebo.
The study found that (-)-deprenyl did not cause hypertensive crises and had a side effect profile similar to that of placebo, indicating it may be a safer alternative to traditional MAO inhibitors.
A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor.Mann, JJ., Aarons, SF., Wilner, PJ., et al.[2019]

References

Monoamine oxidase inhibitors as anti-depressant drugs and as adjunct to L-dopa therapy of Parkinson's disease. [2019]
Deprenyl in Parkinson disease. [2019]
A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. [2019]
L-Deprenyl does not reduce brain damage in global forebrain ischemia in adult gerbils (Meriones ungiculatus). [2019]
Experiences with L-deprenyl in Parkinsonism. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security